Dr. Maky Zanganeh has served as Summit’s Chief Operating Officer and has been a member of the Board of Directors since November 2020.
She has more than 15 years of management, corporate, clinical, and business experience in the pharmaceutical, medical device, and technology industries.
Most recently, Dr. Zanganeh is the Founder & CEO of Maky Zanganeh and Associates (“MZA”), which provides consulting services to businesses in product development, research, and transactions.
Prior to starting and leading MZA, Dr. Zanganeh held multiple leadership positions at Pharmacyclics, Inc., from 2008 to 2015, culminating in her role as Chief Operating Officer, where she oversaw all clinical, research, commercial, and business-related matters. Dr. Zanganeh played a key role both in the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Janssen Biotech, Inc. in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015. The acquisition of Pharmacyclics by AbbVie remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.
Previously, she held senior positions of increasing responsibility within companies such as Robert Duggan & Associates, a private investment firm, and Computer Motion, Inc., a pioneer in robotic surgery.
Dr. Zanganeh earned FierceBiotech’s “Top Women in Biotech” award in 2013. She received her DDS from Louis Pasteur University (France) and her MBA from Schiller International University (France).
Beyond Summit, Dr. Zanganeh is currently a board member for Pulse BioSciences, Inc. and RenovoRx, Inc.
What is Maky Zanganeh's net worth?
The estimated net worth of Maky Zanganeh is at least $1.36 million as of June 23rd, 2020. Dr. Zanganeh owns 352,500 shares of Summit Therapeutics stock worth more than $1,360,650 as of April 26th. This net worth evaluation does not reflect any other investments that Dr. Zanganeh may own. Learn More about Maky Zanganeh's net worth.
How do I contact Maky Zanganeh?
Has Maky Zanganeh been buying or selling shares of Summit Therapeutics?
Maky Zanganeh has not been actively trading shares of Summit Therapeutics during the last quarter. Most recently, on Wednesday, May 12th, Maky Zanganeh bought 389,077 shares of Summit Therapeutics stock. The stock was acquired at an average cost of $5.24 per share, with a total value of $2,038,763.48. Learn More on Maky Zanganeh's trading history.
Who are Summit Therapeutics' active insiders?
Are insiders buying or selling shares of Summit Therapeutics?
In the last year, Summit Therapeutics insiders bought shares 5 times. They purchased a total of 3,131,590 shares worth more than $5,542,117.20. The most recent insider tranaction occured on March, 26th when CEO Mahkam Zanganeh bought 30,000 shares worth more than $112,500.00. Insiders at Summit Therapeutics own 83.7% of the company.
Learn More about insider trades at Summit Therapeutics. Information on this page was last updated on 3/26/2024.
